We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ICRco

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
11 Jun 2020 - 13 Jun 2020

New AI Algorithm Predicts Which Breast Cancer Patients Can Benefit From Additional Therapy

By MedImaging International staff writers
Posted on 01 Jan 2020
Print article
Image: Researchers used AI to improve mammogram image interpretation (Photo courtesy of the Department of Energy’s Oak Ridge National Laboratory).
Image: Researchers used AI to improve mammogram image interpretation (Photo courtesy of the Department of Energy’s Oak Ridge National Laboratory).
Researchers from the Case Western Reserve University (Cleveland, OH, USA) have developed a new artificial intelligence (AI) algorithm that could help better determine which patients diagnosed with the pre-malignant breast cancer (commonly referred to as stage 0) are likely to progress to invasive breast cancer and might benefit from additional therapy over and above surgery alone.

Stage 0 breast cancer is the most common type and known clinically as ductal carcinoma in situ (DCIS), indicating that the cancer cell growth starts in the milk ducts. Once a lumpectomy of breast tissue reveals this pre-cancerous tumor, most women have surgery to remove the remainder of the affected tissue and some are given radiation therapy as well.

The researchers used a computer program to analyze the spatial architecture, texture and orientation of the individual cells and nuclei from scanned and digitized lumpectomy tissue samples from 62 DCIS patients. They found that both the size and orientation of the tumors characterized as “indeterminate” were actually much closer to those confirmed as low risk for recurrence by an expensive genetic test called Oncotype DX. The researchers then validated the features that distinguished the low and high risk Oncotype groups in being able to predict the likelihood of progression from DCIS to invasive ductal carcinoma in an independent set of 30 patients.

“Current testing places patients in high risk, low risk and indeterminate risk—but then treats those indeterminates with radiation, anyway,” said Anant Madabhushi, the F. Alex Nason Professor II of Biomedical Engineering at the Case School of Engineering. “They err on the side of caution, but we’re saying that it appears that it should go the other way—the middle should be classified with the lower risk. “In short, we’re probably overtreating patients. That goes against prevailing wisdom, but that’s what our analysis is finding.”

Related Links:
Case Western Reserve University


Print article
Radcal
CIRS

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.